​

Passage Bio (PASG) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

PASG Stock Forecast

Passage Bio (PASG) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 1835.48% increase from the last price of $0.31.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $0.31

PASG Stock Rating

Passage Bio stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (75.00%), 2 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 6 Strong Sell Sell Hold Buy Strong Buy

PASG Price Target Upside V Benchmarks

TypeNameUpside
StockPassage Bio1835.48%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.31$0.31$0.31
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-5---5
Mar, 25-5---5
Feb, 25-4---4
Jan, 25-4---4
Dec, 24-4---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 19, 2022Madhu KumarGoldman Sachs$6.00$4.9421.46%1835.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 17, 2024Canaccord GenuityBuyBuyhold
Sep 03, 2024Rodman & RenshawBuyinitialise
Nov 14, 2023Raymond JamesOutperformOutperformhold
Dec 15, 2022Chardan CapitalBuyBuyhold
Nov 11, 2022GuggenheimBuyBuyhold
May 17, 2022Raymond JamesOutperformOutperformhold
Jan 19, 2022Goldman SachsNeutraldowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.86$-1.07----
Avg Forecast$-1.85$-0.99$-0.66$-0.74$-0.19$0.60
High Forecast$-1.66$-0.96$-0.53$-0.28$0.10$0.60
Low Forecast$-1.95$-1.00$-0.84$-1.34$-0.45$0.60
Surprise %0.54%8.08%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$1.90M$2.00M$45.01M$156.77M
High Forecast--$1.90M$2.00M$45.01M$156.77M
Low Forecast--$1.90M$2.00M$45.01M$156.77M
Surprise %------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-102.06M$-64.77M----
Avg Forecast$-102.06M$-53.66M$-37.63M$-72.43M$-9.56M$32.66M
High Forecast$-91.14M$-52.37M$-29.03M$-15.23M$5.54M$32.66M
Low Forecast$-106.78M$-54.96M$-46.24M$-73.42M$-24.66M$32.66M
Surprise %-20.69%----

PASG Forecast FAQ

Is Passage Bio stock a buy?

Passage Bio stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Passage Bio is a favorable investment for most analysts.

What is Passage Bio's price target?

Passage Bio's price target, set by 8 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 1835.48% change from the previous closing price of $0.31.

How does Passage Bio stock forecast compare to its benchmarks?

Passage Bio's stock forecast shows a 1835.48% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Passage Bio over the past three months?

  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Passage Bio’s EPS forecast?

Passage Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.66, marking a -38.32% decrease from the reported $-1.07 in 2024. Estimates for the following years are $-0.74 in 2026, $-0.19 in 2027, and $0.6 in 2028.

What is Passage Bio’s revenue forecast?

Passage Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $1.9M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $2M, followed by $45.01M for 2027, and $156.77M for 2028.

What is Passage Bio’s net income forecast?

Passage Bio's net income forecast for the fiscal year ending in December 2025 stands at $-37.634M, representing a -41.89% decrease from the reported $-64.767M in 2024. Projections indicate $-72.426M in 2026, $-9.564M in 2027, and $32.66M in 2028.